ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.00 Consensus Price Target from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given an average recommendation of “Buy” by the four research firms that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have covered the stock in the last year is $80.00.

Several equities analysts have recently issued reports on the company. Truist Financial upped their price target on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Capital One Financial started coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. Guggenheim reissued a “buy” rating and set a $77.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Finally, HC Wainwright raised their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Monday, March 4th.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $67.36 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57. The firm has a market cap of $1.42 billion, a P/E ratio of 80.19 and a beta of 0.80. The business’s fifty day moving average is $66.72 and its two-hundred day moving average is $59.25. ANI Pharmaceuticals has a 52 week low of $38.91 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The business had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. Equities research analysts forecast that ANI Pharmaceuticals will post 3.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Muthusamy Shanmugam sold 7,414 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $66.33, for a total transaction of $491,770.62. Following the sale, the chief operating officer now owns 825,206 shares in the company, valued at approximately $54,735,913.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $66.33, for a total transaction of $491,770.62. Following the transaction, the chief operating officer now directly owns 825,206 shares of the company’s stock, valued at approximately $54,735,913.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP James G. Marken sold 24,338 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $66.37, for a total value of $1,615,313.06. Following the transaction, the senior vice president now directly owns 124,492 shares in the company, valued at $8,262,534.04. The disclosure for this sale can be found here. Insiders have sold 176,803 shares of company stock worth $11,695,866 in the last 90 days. Insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its holdings in ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 248 shares during the period. BluePath Capital Management LLC acquired a new stake in ANI Pharmaceuticals during the third quarter worth approximately $34,000. Pacer Advisors Inc. bought a new stake in ANI Pharmaceuticals in the fourth quarter worth approximately $41,000. AJOVista LLC bought a new position in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $58,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $132,000. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.